Dr. Kristin Lyerly joins Miles Baker straight from her own doctor’s appointment to break down a bombshell just dropped on Truth Social: President Trump’s plan to impose a 100% tariff on imported generic drugs within two years, escalating to 200% the year after. The stated goal is reshoring pharmaceutical manufacturing to the U.S., but Miles and Dr. Lyerly dig into why the math, the timeline, and the incentives don’t add up.
Generic drugs run on razor-thin margins that make U.S. manufacturing nearly impossible, and the staggering reality that six in ten Americans already worry about affording their prescriptions, with one in five rationing their medication. The conversation turns to India’s outsized role supplying roughly half of U.S. generic prescriptions by volume, and what could happen if manufacturers start looking to diversify away from the American market well before any tariffs even take effect.
Dr. Lyerly makes the case that if the administration were serious about reshoring production, it would be working with Congress on bills like the PILLS Act, MEDS Act, and MAPS Act, which offer incentives rather than blunt-force tariffs. They also note that this policy arrives as a “Plan B” after an earlier version was ruled illegal, raising the likelihood of legal challenges and a long stretch of uncertainty — not exactly the environment that encourages companies to invest in new manufacturing plants.
